Raymond James Financial
ABCL icon

Raymond James Financial’s AbCellera Biologics ABCL Stock Holding History

Raymond James Financial’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
289,836
+42,786
+17% +$154K ﹤0.01% 3832
2025
Q4 		$845K Buy
247,050
+208,632
+543% +$931K ﹤0.01% 3892
2025
Q3 		$193K Buy
38,418
+10,369
+37% +$45.7K ﹤0.01% 4632
2025
Q2 		$96.2K Buy
28,049
+4,070
+17% +$10.1K ﹤0.01% 4892
2025
Q1 		$53.5K Buy
23,979
+4,478
+23% +$12.8K ﹤0.01% 4636
2024
Q4 		$57.1K Buy
+19,501
New +$54.3K ﹤0.01% 4593

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's ABCL Position: Q1 2026 in Review

Raymond James Financial increased its AbCellera Biologics (ABCL) stake by 17% in Q1 2026, buying an estimated $154K and bringing the position to 289,836 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3832.

Raymond James Financial first reported a position in ABCL in Q4 2024 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Raymond James Financial held 289,836 shares of AbCellera Biologics worth $1.01M as of Q1 2026.
  • Raymond James Financial bought 42,786 AbCellera Biologics shares in Q1 2026, an estimated $154K.
  • AbCellera Biologics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3832 holding.
  • Raymond James Financial first reported a position in AbCellera Biologics in Q4 2024 and has held it in 6 quarters since.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.